Cardiac Safety London

Event Date:
Wednesday 20th May 2020 - 10am – 3.30pm BST
Location:
Online Event
View ProgramView Program

To help to enrich and speed up your drug development programs, join us for a day of discovery as global experts in Cardiology, Pharmacology and Diabetes discuss the latest state of the art methods in early phase clinical research. The event will provide insight to enable better patient outcomes, efficiency, and cost-effectiveness in global drug development.

The 20th of May also is World Clinical Trials Day celebrating the anniversary of the first clinical trial by James Lind in 1747 into the causes of scurvy on board the HMS Salisbury. On this occasion, we will also showcase work from our Research Institute, our not-for-profit affiliate dedicated to academic research.


Programme

  • Updates on the CSRC white paper on cardiac safety assessments of anti-diabetic medicines
  • Waveform analysis and measurements of QT subintervals
  • Repolarization disturbances in type 1 long QT syndrome patients
  • Cardiac safety embedded in adaptive clinical trials
  • Sex differences in cardiac risk
  • Regulatory updates in drug development
  • Preclinical science and models in cardiac safety assessments
  • Modelling and statistics of pharmacodynamic markers

Click here to view the agenda

This is an online event, to express an interest in this event or to learn more details please contact Jack Wilmott on j.wilmott@richmondpharmacology.com

Latest news

Upcoming Event

The 41st Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

4 – 5 December 2020
The 41st Annual Scientific meeting focuses on international collaboration in the pursuit of drug discovery and drug development.
View event

Contributing to our community in 2020

December 17, 2020
Richmond Pharmacology has a long-standing tradition of supporting local, national, and international charities and 2020 is no exception.
Read more

Richmond Pharmacology supports Cardior Pharmaceuticals with the pioneering trial of an oligonucleotide-based drug in heart failure patients

December 14, 2020
Richmond Pharmacology is delighted to welcome the positive Phase Ib results of Cardior Pharmaceuticals lead compound CDR132L for heart failure.
Read more

Marking a milestone for gene editing

November 10, 2020
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001
Read more